Masp-2-targetting antibodies and uses thereof
AssigneeInmagene Pte. Ltd.
InventorsChongtian GUO, Run LEI, Pengcheng FAN, Lihua FAN, Zhihao XU, Qiang SUN, Jonathan Jian WANG
Life of this patent
Estimating the term…
Abstract
Disclosed herein are anti-MASP-2 antibodies and antigen-binding fragments, polynucleotides encoding the antibodies and antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and antigen-binding fragments. Uses of the anti-MASP-2 antibodies and antigen-binding fragments described herein in treatment of conditions and disorders associated completement activation are also disclosed.
Claims46
An antibody or antigen-binding fragment thereof that specifically binds human MASP-2, comprising:
- (1) as defined by Kabat,
- (a) a light chain variable region (VL) comprising VL CDR1, VL CDR2, VL CDR3 having the amino acid sequences of SEQ ID NOs:
- 7, 9, and 11, respectively;
- or a variant thereof having up to about 5 amino acid substitutions, additions, and/or deletions in the VL CDRs;
- and/or
- (b) a heavy chain variable region (VH) comprising VH CDR1, VH CDR2, VH CDR3 having the amino acid sequences of SEQ ID NOs:
- 12, 16, and 18, respectively;
- or a variant thereof having up to about 5 amino acid substitutions, additions, and/or deletions in the VH CDRs;
- or
- (2) as defined by IMGT,
- (a) a VL comprising VL CDR1, VL CDR2, VL CDR3 having the amino acid sequences of SEQ ID NOs:
- 8, 10, and 11, respectively;
- or a variant thereof having up to about 5 amino acid substitutions, additions, and/or deletions in the VL CDRs;
- and/or
- (b) a VH comprising VH CDR1, VH CDR2, VH CDR3 having the amino acid sequences of SEQ ID NOs:
- 13, 17, and 19, respectively;
- or a variant thereof having up to about 5 amino acid substitutions, additions, and/or deletions in the VH CDRs.
An antibody or antigen-binding fragment thereof that specifically binds human MASP-2, comprising:
- (a) a VL having at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:
- 21;
- and/or
- (b) a VH having at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:
- 22.
An antibody or antigen-binding fragment thereof that specifically binds human MASP-2, comprising
- (a) a VL comprising VL CDR1, VL CDR2, and VL CDR3 from a VL having the amino acid sequence of SEQ ID NO:
- 21;
- and/or
- (b) a VH comprising VH CDR1, VH CDR2, and VH CDR3 from a VH having the amino acid sequence of SEQ ID NO:
- 22.
An antibody or antigen-binding fragment thereof that specifically binds the protease domain of human MASP-2, wherein the antibody or antigen binding fragment:
- (1) binds human MASP-2 with a KD that is 1 nM or less, measured by SPR;
- (2) blocks C4 activation with an IC50 of 0.1 μg/mL or less, measured in vitro;
- (3) blocks C3 activation with an IC50 of 0.1 μg/mL or less, measured in vitro;
- (4) blocks MAC activation with an IC50 of 0.1 μg/mL or less, measured in vitro;
- (5) does not affect the classical or alternative pathway of completement activation;
- or
- (6) any combination of (1)-(5).
Dependencies are inferred from the claim text.